None listed
Conditions
Brief summary
This project aims to developing a performance test battery that can be utilised by sleep physicians in order to assess an obstructive sleep apnea (OSA) subject's performance and sleepiness level after they have been treated with continuous positive airway pressure (CPAP). To facilitate this OSA subjects' performances will be assessed by a number of psychomotor tasks, cognitive tasks and objective measures of sleepiness. OSA subjects and also controls will be tested during their normal state and also during a sleep deprived state so that comparisons can be made between the two groups and across the two different conditions.
Interventions
This randomised, case-controlled project aims to aid in developing a performance test battery that can be utilised by sleep physicians in order to assess an obstructive sleep apnea (OSA) subject’s performance and sleepiness level after they have been treated with continuous positive airway pressure (CPAP). Subjects will be given an 'Autoset' CPAP machine and sleep-wake activity will be assessed for 7 days using actigraphy. Subjects will then report to the laboratory where they will undergo two overnight polysomnographies (PSG) whilst using CPAP. During the waking hours subjects will complete a variety of neurocognitive tasks and questionnaires. After a washout period of 28 days subjects will repeat the protocol, except following the first PSG they will complete a 41 hours and 55 min sleep deprivation period. A recovery night will follow the sleep deprivation period.
Sponsors
Study design
Eligibility
Inclusion criteria
Diagnosed OSA by night polysomnography with an apnea hypopnea index (AHI) =10, receiving optimal CPAP treatment for at least 6months, Epworth Sleepiness Score (ESS) = 10, absence of significant co-morbidities.
Exclusion criteria
Previous cerebral vascular accident (CVA), head injury, history of neurological disorders (including depression), history of unstable hypertension (blood pressure (BP) cannot exceed>160mmHg/.100mmHg), psychotropic drug use, received investigational drug within last 60 days, significant respiratory disease, significant renal or hepatic impairment, use of stimulant/sleeping tablets, shift workers and non-English speaking subjects.